

In the Brief Description of the Figures:

~~Page 31~~, line 17, after "WSXWS" insert --(SEQ ID NO:9) --;

~~Page 32~~, line 20, after "murine" insert --(SEQ ID NOS: 1 and 2, respectively)--, and after "genes" insert --(SEQ ID NOS: 3 and 4, respectively)--; and

~~Page 33~~, line 12 after "NR4" insert --(SEQ ID NOS: 10 and 11)--.

IN THE SPECIFICATION:

Please delete the sequence listing submitted on January 4, 1999 and insert the enclosed substitute sequence listing.

REMARKS

In the Communication dated January 6, 2001, the Examiner has objected to the amendment filed October 16, 2000 as allegedly not fully responsive to the Office Action dated April 11, 2000. The Examiner specifically alleges that Figure 1 refers "to WSXWS residues...but no reference by SEQ ID NO: is made to said protein sequence." The Examiner further alleges that Figures 7 and 10 "refer to [a] polynucleotide sequence or an amino acid sequence, but no reference by SEQ ID NO: is made to said sequences in the Brief Description of the Figures."

In response, applicants have amended the Brief Description of the Figures to include reference to SEQ ID NO:9, which corresponds to the sequence identified as "WSXSW" in Figure 1. A substitute sequence listing reflecting SEQ ID NO:9 is also provided. No new matter has been added.

Applicants have also amended the Brief Description of the Figures to include reference to SEQ ID NOS:1-4 in Figure 7 and to SEQ ID NOS:10 and 11 in Figure 10. No new matter has been added.

Thus, in view of the foregoing amendments and remarks, applicants respectfully submit that the present application is in condition for allowance, which action is earnestly solicited.

Respectfully submitted,



Frank S. DiGiglio
Registration No. 31,346

SCULLY, SCOTT, MURPHY & PRESSER
400 Garden City Plaza
Garden City, New York 11530
(516) 742-4343

PIB/bb